Final approval and trading of the Company shares are subject to fulfilling customary CSE requirements. Safe Supply and Origin anticipate that trading will commence within the month of September 2023 for which shareholders and stakeholders will receive due notice.
Upon trading, the Company will have fulfilled its transactional requirements detailed in the definitive agreement pertaining to the release of funds escrowed (See Press Release dated August 1, 2023) totalling $2,386,000 through subscription receipts.
At the time of trading, the resulting issuer will change its name to “Safe Supply Streaming Co Ltd” under a trading symbol to “SPLY” and will begin to fund investments in the burgeoning safe supply ecosystem.
Safe Supply is the world’s first company investing in the legal and regulated supply of drugs that traditionally have been accessible only through the illicit drug market. Led by the pioneers behind the cannabis and psychedelics industries, Safe Supply is actively deploying capital in the third wave of drug reform, specifically on ending the fentanyl crisis and emerging opportunities for the coca plant. The company’s focus is investing and incubating companies across the ecosystem to address the physical, financial and emotional damage from drug abuse with promising products, solutions and technologies across the entire safe supply value chain.
Learn more at www.safesupplystreaming.com and follow Safe Supply on LinkedIn, Twitter, and Instagram.
About Origin Therapeutics
Origin is an investment issuer that has historically focused on making equity investments in psychedelics-industry-related companies to provide investors with diverse exposure to the sector. On December 8, 2022, Origin announced that its board of directors had initiated a review process to consider, review and evaluate strategic alternatives for Origin.